Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2008

AMRI Lands a $4M Milestone Fee from Bristol-Myers Squibb

  • AMRI is due to receive a $4 million milestone payment from Bristol-Myers Squibb as a result of submitting an application to the Canadian regulatory agency to begin Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. A Clinical Trial Application was filed with the Health Products and Food Branch, Health Canada.

    The compound under consideration is a biogenic amine reuptake inhibitor acting at multiple targets. AMRI and Bristol-Myers Squibb have collaborated to develop treatments for depression and diseases of the central nervous system.
    This is the second milestone for this first candidate to emerge from the partnership; AMRI announced a $1.5 million fee a year ago when this compound was nominated by BMS for development.


Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »